# A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

> **NCT03083041** · PHASE2 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 210 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** SHR-1210
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03083041
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2022-04-22
- **Final completion:** 2022-04-22
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083041, "A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03083041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*